|
注册号: Registration number: |
ChiCTR2100044769 |
|
最近更新日期: Date of Last Refreshed on: |
2021-10-18 00:36:07 |
|
注册时间: Date of Registration: |
2021-03-27 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
王洁医师:请于伦理委员会批准后才开始征募参试者,并与我们联系上传伦理批件;请上传研究计划书、知情同意书模板。 鼻内胰岛素预处理对老年髋部骨折修复术术后认知功能障碍发生率的影响 |
|
Public title: |
Effects of intranasal insulin preconditioning on the incidence of cognitive dysfunction after hip fracture repair in the elderly |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
鼻内胰岛素预处理对老年髋部骨折修复术术后认知功能障碍发生率的影响 |
|
Scientific title: |
Effects of intranasal insulin preconditioning on the incidence of cognitive dysfunction after hip fracture repair in the elderly |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王洁 |
研究负责人: |
刘朋 |
|
Applicant: |
Wang Jie |
Study leader: |
Liu Peng |
|
申请注册联系人电话: Applicant telephone: |
+86 13696233635 |
研究负责人电话:
Study leader's |
+86 13284473704 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
2591229293@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
liupeng2010aa@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
河北省石家庄市桥西区自强路139号 |
研究负责人通讯地址: |
河北省石家庄市桥西区自强路139号 |
|
Applicant address: |
139 Ziqiang Road, Qiaoxi District, Shijiazhuang, Hebei. |
Study leader's address: |
139 Ziqiang Road, Qiaoxi District, Shijiazhuang, Hebei. |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
河北医科大学第三医院 |
||
|
Applicant's institution: |
The Third Hospital of Hebei Medical University |
||
|
研究负责人所在单位: |
河北医科大学第三医院 |
||
|
Affiliation of the Leader: |
The Third Hospital of Hebei Medical University |
||
|
是否获伦理委员会批准: |
否 |
||
|
Approved by ethic committee: |
No |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦理委员会批件附件: Approved file of Ethical Committee: |
||
|
批准本研究的伦理委员会名称: |
|
||
|
Name of the ethic committee: |
|
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2013-08-26 00:00:00 | ||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
河北医科大学第三医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Third Hospital of Hebei Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
河北省石家庄市桥西区自强路139号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
139 Ziqiang Road, Qiaoxi District, Shijiazhuang, Hebei. |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
石家庄市卫生厅 |
||||||||||||||||||||||
|
Source(s) of funding: |
Shijiazhuang Health Department |
||||||||||||||||||||||
|
研究疾病: |
老年患者髋部骨折手术 |
||||||||||||||||||||||
|
Target disease: |
Surgery for hip fracture in elderly patients |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
阐明在全身麻醉下行髋部骨折修复术的老年患者,术前多次行经鼻注射胰岛素,是否能减少此类人群术后认知功能障碍发生率,降低促炎症因子水平,为临床防治POCD提供新的措施。 |
||||||||||||||||||||||
|
Objectives of Study: |
To clarify whether repeated nasal injection of insulin before surgery can reduce the incidence of postoperative cognitive dysfunction in elderly patients undergoing hip fracture repair under general anesthesia, reduce the level of pro-inflammatory factors, and provide new measures for the clinical prevention and treatment of POCD. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.有精神疾病史或精神疾病家族史; |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Patients with a history of mental illness or family history of mental illness; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-07-01 00:00:00至 To 2023-08-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2021-07-01 00:00:00 至 To 2023-08-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
使用计算机SPASS软件完全随机化分组,按I组和C组1:1的比例产生随机数字及随机编号。I组使用胰岛素20IU,C组使用生理盐水2ml。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The computer SPASS software was used to completely randomize the groups, and random numbers and random numbers were generated according to the ratio of 1:1 between group I and group C.Group I received 20IU of insulin, while group C received 2 mL of normal saline. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
试验对象对所使用药物采用盲法,量表评估人员对试验用药及分组采用盲法。 |
|
Blinding: |
Blind method for subjects and evaluators. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
采用网络平台 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
use web-based public database |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
使用病历记录表和电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Use of medical records and electronic collection and management systems |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |